32 Leading Global Fashion and Textile Companies Make Commitments on Climate, Biodiversity and Oceans
FT Indxx Innovative Transaction & Process UK Regulatory Announcement: Net Asset Value(s)
FT US Small Cap Core AlphaDEX UCITS ETF UK Regulatory Announcement: Net Asset Value(s)
FT US Equity Income ETF UK Regulatory Announcement: Net Asset Value(s)
FT ETF US IPO Index UK Regulatory Announcement: Net Asset Value(s)
FT ETF Global Equity UK Regulatory Announcement: Net Asset Value(s)
FT ETF Global Equity UK Regulatory Announcement: Net Asset Value(s)
MMC UAV is Improving its Industrial UAV Leadership by Industrial Synergy Strength
FT US Large Cap Core AlphaDEX ETF UK Regulatory Announcement: Net Asset Value(s)
FT US Large Cap Core AlphaDEX ETF UK Regulatory Announcement: Net Asset Value(s)
-
FT US Large Cap Core AlphaDEX ETF UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 22.08.2019 FEX IE00B8X9NW27 2,230,002.00 USD 103,747,148.36 46.523 Contacts First Trust Global Funds PLC
-
Mongolian Mining Corporation announces 2019 Interim Results
HONG KONG, Aug 23, 2019 - (ACN Newswire) - Mongolian Mining Corporation ("MMC", or together with its subsidiaries, the "Group"; stock code: 975), the largest producer and exporter of washed hard coking coal ("HCC") in Mongolia, today announced its unaudited interim results for the six months ended 30 June 2019 ("1H2019" or the "reporting period"). During the reporting period, the Group generated a total revenue of USD325.6 million, an increase of nearly 20% (1H2018: USD272.2 million). The Group sold approximately 2.0 Mt of HCC, an increase of 14.0% as compared to 1.7 Mt of HCC sold during the same period in 2018. The average selling price ("ASP") for HCC was USD147.0 per tonne in 1H2019 (ASP in 1H2018: USD146.1 per tonne). Gross profit amounted to approximately USD129.9 million in 1H2019, representing an increase of 20.1% year-on-year (1H2018: USD108.1 million); while profit attributable to equity shareholders of the Company for 1H2019 surged by 59.4% to approximately USD47.1 million (1H2018: USD29.5 million). Dr. Battsengel Gotov, Chief Executive Officer of MMC, said, "We are pleased to report sound financial and operational performance for the period, highlighted by nearly 20% revenue growth and over 59% growth in profit attributable to equity shareholders. Building on the strong first half of the year, we look to continuously push our production and sales volumes by utilizing our existing coal mining and processing capacity, optimizing our transportation and logistics efficiency and expanding relations with our end-user customers' base. Also we shall remain focused on our commitment to safe and responsible mining operations. About Mongolian Mining Corporation (Stock code: 975)Mongolian Mining Corporation ("MMC" or "the Group", SEHK: 975) is the largest producer and exporter of washed HCC in Mongolia. It owns and operates two open-pit coking coal mines, the Ukhaa Khudag deposit located within the Tavan Tolgoi coal formation, as well as the Baruun Naran coking coal deposit, both located in South Gobi, Mongolia. MMC was listed on The Stock Exchange of Hong Kong Limited in October 2010. To learn more about the Group, please visit MMC's website at: www.mmc.mn. Enquiries:Strategic Financial Relations LimitedCindy Lung +852 2864 4867 cindy.lung@sprg.com.hkStephanie Liu +852 2864 4852 stephanie.liu@sprg.com.hkDesiree Shung +852 2114 2200 desiree.shung@sprg.com.hkFrom left to right: Dr. Battsengel Gotov (Executive Director & Chief Executive Officer), Ms. Ulemj Baskhuu (Chief Financial Officer) Copyright 2019 ACN Newswire. All rights reserved. www.acnnewswire.com
-
First Trust Cloud Computing UCITS ETF UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Cloud Computing UCITS ETF 22.08.2019 CPQ IE00BFD2H405 950,002.00 USD 22,817,285.96 24.018 Contacts First Trust Global Funds PLC
-
FT Dow Jones Internet UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones Internet UCITS ETF 22.08.2019 FDNU IE00BG0SSC32 450,002.00 USD 8,578,957.35 19.064 Contacts First Trust Global Funds PLC
-
FT FactorFX UCITS ETF UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 22.08.2019 FTFX IE00BD5HBQ97 150,002.00 USD 3,068,458.08 20.456 Contacts First Trust Global Funds PLC
-
Cantargia and BioWa Extend Ongoing Collaboration around the POTELLIGENT® Technology
LUND, Sweden & PRINCETON, N.J.--(BUSINESS WIRE)--Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology. Since the original agreement allowing use of POTELLIGENT® Technology was signed in 2015, Cantargia has advanced CAN04 to phase IIa clinical development for potential use in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC). Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The POTELLIGENT® technology generates antibodies with enhanced antibody dependent cellular cytotoxicity (ADCC). The investigational antibody CAN04 binds IL1RAP with high affinity and functions through both ADCC and blockade of interleukin 1 signaling. CAN04 is currently produced in a Chinese Hamster Ovary (CHO) cell line provided by BioWa which has been engineered using POTELLIGENT® Technology. The extended agreement enables Cantargia to create and use additional CHO cell lines engineered using POTELLIGENT® Technology and develop and commercialize CAN04 made through such CHO cell line. With CAN04 having reached phase IIa clinical development, the next step in the production development is to further reduce production costs using various process improvements as well as scaling up, and Cantargia and BioWa have agreed to extend the current license to include additional opportunities. “We are extremely pleased with our collaboration with BioWa and the amended agreement is a logical step in our long-term relationship. Given the successful advances of CAN04, optimization of the production process to reduce cost is part of the CAN04 development plan”, Göran Forsberg, Cantargia’s CEO says. “We believe that this extension of the license agreement would add benefits into the fruitful collaboration between Cantargia and BioWa.” said Takeshi Masuda, BioWa’s President and CEO. “We are very pleased that this amended agreement could support the innovative program going forward”. This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on August 23, 2019. About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is conducting both monotherapy and combination therapy. Cantargia's other project, CANxx, is in the research phase and is aiming to develop an IL1RAP binding antibody optimised for the treatment of autoimmune and inflammatory diseases. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com. About BioWa BioWa is a wholly-owned subsidiary of Kyowa Kirin Co., Ltd. (“Kyowa Kirin”), a leading biopharmaceutical company in Japan. BioWa is the exclusive worldwide licensor of the POTELLIGENT® Technology for creating antibody molecules with enhanced ADCC, and COMPLEGENT® Technology for that with enhanced Complement-Dependent Cytotoxicity (“CDC”). BioWa has been offering POTELLIGENT® / COMPLEGENT® Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight against life-threatening and debilitating diseases. About POTELLIGENT® Technology POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyl transferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT® antibodies are being investigated in human clinical trials and a growing body of evidence has confirmed the clinical benefit of this technology. As of today, POTELLIGENT® Technology has been used to develop and commercialize products for markets in Japan, US and Europe, including treatments for cutaneous T-cell lymphoma, adult T-cell leukemia lyphoma, peripheral T-cell lymphoma, and severe eosinophilic asthma. POTELLIGENT® and COMPLEGENT® are registered trademarks of Kyowa Kirin Co., Ltd. Contacts For further information, please contact Cantargia: Göran Forsberg, CEO Telephone: +46 (0)46-275 62 60 E-mail: goran.forsberg@cantargia.com BioWa: Shintaro Hasegawa, Director, Business Development Telephone: +1 609 580 7340 E-mail: hasegawa.shintaro@biowa.com
-
TechnipFMC UK Regulatory Announcement: TechnipFMC plc: Notification of Major Interest in Shares
LONDON--(BUSINESS WIRE)-- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: TECHNIPFMC PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) An acquisition or disposal of voting rights [X] An acquisition or disposal of financial instruments An event changing the breakdown of voting rights Other (please specify)iii: 3. Details of person subject to the notification obligationiv Name State Street Corporation City and country of registered office (if applicable) Boston, MA USA 4. Full name of shareholder(s) (if different from 3.)v Name City and country of registered office (if applicable) 5. Date on which the threshold was crossed or reachedvi: 19th August 2019 6. Date on which issuer notified (DD/MM/YYYY): 21st August 2019 7. Total positions of person(s) subject to the notification obligation % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights of issuervii Resulting situation on the date on which threshold was crossed or reached 5.00% 0.00% 5.00% 446,481,753 Position of previous notification (if applicable) 4.99% 0.00% 4.99% 8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii A: Voting rights attached to shares Class/type of shares ISIN code (if possible) Number of voting rightsix % of voting rights Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) CUSIP BDSFG98 22,331,010 5.00% SUBTOTAL 8. A 22,331,010 5.00% B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of financial instrument Expiration datex Exercise/ Conversion Periodxi Number of voting rights that may be acquired if the instrument is exercised/converted. % of voting rights N/A SUBTOTAL 8. B 1 B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of financial instrument Expiration datex Exercise/ Conversion Period xi Physical or cash settlementxii Number of voting rights % of voting rights N/A SUBTOTAL 8.B.2 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) These shares are registered in Nominee Company names on behalf of a range of clients who are the beneficial owners of these shares. Namexv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold State Street Global Advisors (Japan) Co., Ltd 0.53% 0.00% 0.53% State Street Global Advisors Asia Limited 0.02% 0.00% 0.02% State Street Global Advisors Australia Limited 0.03% 0.00% 0.03% State Street Global Advisors Inc 3.64% 0.00% 3.64% State Street Global Advisors Ireland Limited 0.58% 0.00% 0.58% State Street Global Advisors Limited 0.13% 0.00% 0.13% State Street Bank & Trust 0.07% 0.00% 0.07% 10. In case of proxy voting, please identify: Name of the proxy holder The number and % of voting rights held The date until which the voting rights will be held 11. Additional informationxvi Place of completion London Date of completion 21st August 2019 Contacts TechnipFMC plc
-
JNA Awards honouring three retail pioneers for their lifetime achievements
HONG KONG, Aug. 23, 2019 /PRNewswire/ -- The JNA Awards is honouring three outstanding leaders from the jewellery industry as Recipients of the Lifetime Achievement Award. Sharing the same passion and a dream, these entrepreneurs have each transformed the retail sector and influence the industry in their own respective way. Cao Thi Ngoc Dung, Founder and Chairperson of Phu Nhuan Jewelry Joint Stock Company (PNJ); Hung Ming Li, Founder and Chairman of Taiwan-based Chii Lih Coral (Chii Lih); and Wang Chun Li, Managing Director and General Manager of Beijing Caishikou Department Store (Beijing Caibai) will be honoured at the JNA Awards Ceremony and Gala Dinner on 17 September during the September Hong Kong Jewellery & Gem Fair. "The JNA Awards was founded to recognise innovative ideas, best-in-class business practices and successful business models. Honouring these ladies with such vision and perseverance exemplifies what this award stands for," explained Letitia Chow, Chairperson of the JNA Awards and Director of Business Development - Jewellery Group at Informa Markets. Hung Ming Li, Founder and Chairman of Chii Lih Wang Chun Li, Managing Director and General Manager of Beijing Caibai Cao Thi Ngoc Dung, Founder and Chairperson of PNJ Cao Thi Ngoc Dung Cao began with the intention of reviving the traditional Vietnamese jewellery industry. Believing that "anything that can be made overseas could be made domestically", she persevered and engaged in self-research by joining jewellery expos, visiting and studying large jewellery factories across Asia, and investing on state-of-the-art technology that would become essential in growing PNJ. Under Cao's leadership, PNJ has grown from an initial team of 20 to become the largest jewellery retailer in Vietnam employing nearly 7,000 staff. Its products are carried in nearly 400 outlets in 55 provinces, and PNJ has brought Vietnamese jewellery to the global scale by exporting to 13 countries. In 2012, PNJ was ranked 16th in the top 500 list of the world's largest jewellery, manufacturing and trading companies by Plimsoll UK. She was also recognised as one of Forbes Vietnam's Top 50 Most Influential Women in 2018 and 2019; and one of its Top 50 Most Powerful Women Entrepreneurs in Asia in 2016. On receiving the Lifetime Achievement Award, Cao said, "I would like to sincerely thank the JNA Awards organiser for this honour. This award has brought me pride and has motivated me even more in contributing to the growth of PNJ and the Vietnamese jewellery industry in general." Click here to view full press release on Cao Thi Ngoc Dung. Hung Ming Li Hung established Chii Lih in 1973 with the mission of promoting Taiwan's most precious gem corals to the world. Under her leadership, the company has evolved from being a small traditional coral processing factory and wholesaler in Kaohsiung, to a world-renowned jewellery enterprise over the past 40 years. "Looking at the coral dredged up from the sea, my heart was deeply touched. I have been thinking that these are very precious marine resources and national treasures from Taiwan. We should bring such a local industry to greater heights of development and glorify it from our land," she shared. While many decided to leave the coral gemstone industry when the economy declined in the '90s, Hung stayed true to her convictions that coral would always be one of the most important treasures of Taiwan. Along with her staff, she persevered and continued to weather the economic turmoil. To stay on course, Hung actively participated in international jewellery tradeshows in Asia, America and Europe to strengthen Taiwan's reputation as the "Coral Kingdom," and is eventually recognised as a leading company in this sector. Click here to view full press release on Hung Ming Li. Wang Chun Li When Wang was the head of yellow gold products department at Beijing Caibai, which was operating as a department store at that time, she led a modest team to create a special strategy for selling yellow gold jewellery. Through the years, Wang went from one achievement to the next, becoming the first enterprise in China to sell CNY 100 million (USD 14.5million) of yellow gold in 1994. In the same year, Wang, together with her management team, successfully restructured Beijing Caibai from a state-owned company to a private share-holding structure by raising funds from its employees and legal person. Beijing Caibai eventually became a specialised gold jewellery store, consistently topping sales chart in Beijing and retail stores in China for 29 years. Besides from providing excellent after-sales service, she was insistence in protecting consumers on the authenticity by ensuring products sold under her obtained certification from global standardisation and exercising strict quality-control along the supply chain. Under her leadership, the company was named "The First Yellow Gold House in Beijing" by the Beijing Municipal Commission of Commerce in 1997, joined the Shanghai Gold Exchange in 2001, and was recognised as "The First Gold House in China" by the Association of China Commercial Enterprise Management in 2004. Nowadays, gold, platinum, jade and diamond jewellery are sold at Beijing Caibai, it has been honoured as "Global Leading Platinum Jewellery Enterprise" and "The First Coloured Gemstone House in China" by Platinum Guild International and The International Colored Gemstone Association respectively. Click here to view full press release on Wang Chun Li. The JNA Awards is supported by Headline Partners Chow Tai Fook Jewellery Group, the Shanghai Diamond Exchange, and DANAT, together with Honoured Partners KGK Group, China Gems and Jade Exchange, and Guangdong Land Holdings Limited. For more information, visit http://www.JNAawards.com/ or contact:JNA Awards MarketingInforma Markets +852 2516-2184marketing@jnaawards.com Notes for Editors: 1. About the Headline Partner 1.1 Chow Tai Fook Jewellery Group Limited (www.chowtaifook.com) Chow Tai Fook Jewellery Group Limited (the "Group"; SEHK stock code: 1929) listed on the Main Board of The Stock Exchange of Hong Kong in December 2011. The Group's vision is to become the most trusted jewellery group in the world. Founded in 1929, the Group's iconic brand "CHOW TAI FOOK" is widely recognised for its trustworthiness and authenticity, and is renowned for its product design, quality and value. A long-standing commitment to innovation and craftsmanship has contributed to the Group's success, along with that of its iconic retail brand, and has been embodied in its rich 90 year heritage. Underpinning this success are our long held core values of "Sincerity - Eternity". The Group's multi-brand strategy comprises the ARTRIUM, JEWELRIA and CTF WATCH brands that are endorsed by the CHOW TAI FOOK master brand, in addition to other brands including HEARTS ON FIRE, T MARK, SOINLOVE and MONOLOGUE. The Group's commitment to sustainable growth is anchored in its "Smart+" strategy, which is in place to promote long term innovation in the business, in people and in culture. Another asset underpinning sustainable growth is a sophisticated and agile business model. This supports the Group by fostering excellence and extending opportunities along the entire value chain to communities and industry partners across the world. With an extensive retail network in Greater China, Japan, Korea, Southeast Asia and the United States, and a fast-growing e-commerce business, the Group is implementing effective online-to-offline ("O2O") strategies to succeed in today's omni-channel retail environment. 1.2 Shanghai Diamond Exchange (www.cnsde.com) Authorised by the State Council, the Shanghai Diamond Exchange (SDE) is the only diamond exchange body in China; and provides diamond dealers a fair and safe transaction venue under close supervision. It also enjoys a favourable taxation policy and is operated in accordance with international best practices of the diamond industry. Established in 2000, the SDE is a non-profit, self-regulating membership organisation and a member of the World Federation of Diamond Bourses. 1.3 Bahrain Institute for Pearls and Gemstones -- DANAT (www.danat.bh) The Bahrain Institute for Pearls and Gemstones (DANAT) was established in 2017, as an initiative of HRH Prince Salman bin Hamad bin Isa Al Khalifa, Crown Prince, Deputy Supreme Commander and First Deputy Prime Minister of the Kingdom of Bahrain. DANAT was formed as a wholly owned subsidiary of the Bahrain Mumtalakat Holding Company (Mumtalakat), the sovereign wealth fund of the Kingdom. DANAT evolved from the Pearl & Gem Testing Laboratory of Bahrain (the first laboratory of its kind in the region), which was established in 1990. It was formed to expand upon and enhance the excellent work of the laboratory, with the vision of becoming the world's preferred institute for natural pearl and gemstone third-party verification services and scientific research. Currently, DANAT plays a vital role in protecting and enhancing the public's trust in pearls, gemstones and jewellery. With its offices located at the iconic Bahrain World Trade Centre, the facility aims to establish itself as the window into international markets, serving local and global clients, and bolstering the reputation of the Kingdom as a leading centre for pearl and gemstone expertise. DANAT is an authority on industry standards, scientific knowledge and education, and is committed to the highest standards of professional and personal ethics. It is dedicated to supporting the pearl and gemstone industry and offers training programmes locally, regionally and internationally to a new generation of gemmologists, industry professionals and gemmology enthusiasts. 2. About the Honoured Partners 2.1 KGK Group (www.kgkgroup.com) The KGK Group was founded in 1905 by Kesrimal Kothari and Ghisilal Kothari of Jaipur (India), to trade gemstones between India and Burma. With a global presence across 19 countries today, the privately held group has evolved into one of the most preferred brands in the gemstone and jewellery industry, with a vertically integrated operation. KGK is one of the few conglomerates covering the entire spectrum of mining, sourcing, manufacturing and distribution of coloured gemstones, diamonds and jewellery for over a century. KGK Group has a resilient team of 12,000 employees with operations and offices in Asia, Australia, North and South America, Europe and Africa. Having achieved an impeccable reputation in the gemstone, diamond and jewellery trade, the group has recently diversified into real estate. 2.2 China Gems & Jade Exchange (www.csgje.com) China Gems & Jade Exchange (CGJE) is a national gem and jade trading platform approved by the State Council. China Gems & Jade Exchange adheres to the principle of "Led by Technology, Develop with Innovation", and using the latest real-time traceability, big data, block chains, high-end intelligent technology to solve various bottlenecks in the development of the gemstone industry. At present, two platforms have been built, namely, gemstone trading service platform and intelligent supply chain service platform. CGJE has become the only international gemstone trading service platform with full process tracking service in the industry. In line with the basic principles of " fairness, impartiality and openness", China Gems & Jade Exchange combines the concepts of "innovation, advancement and compliance" to provide high-quality and professional third-party supporting trade services for jewelry enterprises at home and abroad. 2.3 Guangdong Land Holdings Limited (www.gdland.com.hk) Guangdong Land Holdings Limited (GDLAND), with its headquarters in Hong Kong, is listed on The Stock Exchange of Hong Kong Limited, and is a subsidiary of GDH Limited - Guangdong Province's largest conglomerate operating outside Mainland China. GDLAND primarily engages in property development and investment, and in business that include (but are not limited to) the development and operational management of innovative commercial real estate, urban complex and industrial business complex. As the strategic arm of GDH Limited, GDLAND engages in the business development of commercial real estate, as well as urban and industrial complex projects. Its flagship "Buxin Project" is forecast to become the biggest and most advanced jewellery mart in the world. With a lot size of over 87,000 sq.m. and a floor area projected to exceed 700,000 sq.m., the Buxin Project will include a large-scale jewellery trading and exhibition centre along with other facilities. Located in the Buxin area of Luohu district in Central Shenzhen, and close to the Shuibei Gold and Jewellery Base, this prime piece of property is expected to turn the area into one of the most influential gold and jewellery trading and exchange platforms, not just in China, but in the world. 3. About Informa Markets (www.informamarkets.com)Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world's leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com. Photo - https://photos.prnasia.com/prnh/20190822/2559251-1-a?lang=0 Photo - https://photos.prnasia.com/prnh/20190822/2559251-1-b?lang=0 Photo - https://photos.prnasia.com/prnh/20190822/2559251-1-c?lang=0 Logo - https://photos.prnasia.com/prnh/20181024/2277935-1LOGO?lang=0 Related Links :http://www.JNAawards.com/
-
Adocia Announces That the American Arbitration Association Tribunal Dismissed All Claims in Second Phase of Arbitration With Eli Lilly
The American Arbitration Association Tribunal dismissed the second set of claims made by Adocia and the counterclaims filed by Eli Lilly Previous award of USD 11.6 million plus interest to Adocia from first phase of the arbitration is not impacted by this decision Adocia’s intellectual property and financial position remain secure LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC) the biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today that the American Arbitration Association Tribunal (“Tribunal”) governing Adocia’s arbitration claims against Eli Lilly & Company (“Lilly”) dismissed both parties’ claims in the second and final phase of the arbitration between Adocia and Lilly. Adocia filed claims against Lilly for misappropriation and misuse of its confidential information and discoveries and Lilly subsequently filed counterclaims based on allegations that Adocia concealed the discoveries and confidential information which were at issue in Adocia's claims. “We are extremely surprised and disappointed by the Tribunal’s decision to dismiss our claims. Nevertheless, Adocia believes it was our responsibility to defend the rights of our Company and shareholders.” commented Gérard Soula, Chairman and CEO of Adocia. “We remain confident in the value of our strong products portfolio. We stand in a stable financial position and we will benefit from the award from the first arbitration ruling. This allows us to continue the development of our pipeline products, including those in collaboration with our partner, Tonghua Dongbao.” This decision will not impact the August 2018 decision by the Tribunal to award Adocia USD 11.6 million in damages, plus interest, as compensation over a disputed contractual milestone payment. Adocia will hold a conference call to answer shareholders’ questions on August 23rd, 2019. 23 August 2019 at 06:00 pm (CEST) – Conference call in French ID 2507797 Participant International Dial-in Number (France): 0033 (0)805081488 23 August 2019 at 6:30 pm (CEST) – Conference call in English ID 4594976 Participant Toll-Free Dial-In Number (United States): 001 (833) 251-7256 Participant International Dial-In Number (United States): 001 (270) 215-9920 Please, find all dial-in numbers details on: www.adocia.com The following members of Adocia leadership team will conduct the call: Gérard Soula, President and CEO Olivier Soula, R&D Director & Deputy General Manager Valérie Danaguezian, CFO Rémi Soula, Director of Business Development & Legal Affairs About Adocia Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. In the diabetes field, Adocia’s portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring seven clinical-stage products. Additionally, Adocia expanded its portfolio to include the development of treatments of obesity and short bowel syndrome. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application. Adocia’s clinical pipeline includes five novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone® Combo), a rapid-acting formulation of human insulin (HinsBet® U100), and a combination of a prandial insulin with amylin analog pramlintide (ADO09). It also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia. Adocia preclinical pipeline includes combinations of insulin glargine with GLP-1 receptor agonists (BioChaperone® Glargine GLP-1) for the treatment of diabetes, a ready-to-use combination of glucagon and a GLP-1 receptor agonist (BioChaperone® Glucagon GLP1) for the treatment of obesity and a ready-to-use aqueous formulation of teduglutide (BioChaperone® Teduglutide) for the treatment of short bowel syndrome. In 2018, Adocia and Chinese insulin leader Tonghua Dongbao entered into a strategic alliance. In April 2018, Adocia granted Tonghua Dongbao licenses to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The licensing included 50 million dollars upfront and up to 85 million dollars development milestones, plus double-digit royalties on sales. In June 2018, Tonghua Dongbao agreed to manufacture and supply active pharmaceutical ingredients insulin lispro and insulin glargine to Adocia globally, excluding China, to support Adocia’s portfolio development in these territories. Adocia aims to deliver “Innovative medicine for everyone, everywhere.” To learn more about Adocia, please visit us at www.adocia.com. Disclaimer This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the “Risk Factors” section of the Reference Document filed with the French Autorité des marchés financiers on April 12, 2019 (a copy of which is available at www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction. Contacts Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.com Ph.: +33 4 72 610 610 Adocia Press Relations Europe MC Services AG Raimund Gabriel adocia@mc-services.eu Ph.: +49 89 210 228 0 Adocia Investor Relations USA The Ruth Group Tram Bui tbui@theruthgroup.com Ph.: +1 646 536 7035
-
Crypto.com Lists Stratis (STRAT)
Launches Stratis Staking Bonus HONG KONG, Aug. 23, 2019 /PRNewswire/ -- Crypto.com, the pioneering payments and cryptocurrency platform, announced today that it has listed Stratis (STRAT) to its App. STRAT joins a growing list of cryptocurrencies and stablecoins on the Crypto.com platform, such as Bitcoin (BTC), Ether (ETH), Litecoin (LTC), XRP, TrueUSD (TUSD), PAXOS (PAX), and its own MCO and CRO Tokens. Launches Stratis Staking Bonus Stratis (STRAT) is a blockchain-as-a-service provider that supports C# APIs and other familiar frameworks like Microsoft's .NET for developers. Enterprises are able to build their own private blockchains, which can be integrated with the main Stratis blockchain. The Stratis cryptographic token (STRAT) fuels the Stratis Platform and acts as a value transfer vehicle in the Stratis marketplace. With STRAT added to the Crypto.com, users can now purchase it at true cost with no fees - credit card and bank transfer both supported. As Crypto.com also offers the MCO Visa Card, this adds additional utility to STRAT as users can easily convert cryptocurrencies into fiat currencies and spend at over 40m merchants globally. All Crypto.com users that hold STRAT in the App are entitled to receive STRAT staking bonus, on a monthly basis. For distribution details, see here. About Stratis Stratis is an enterprise-grade Blockchain development platform that offers end-to-end solutions for development, testing, and deployment of native C# blockchain and decentralized applications (dApps) on the .NET framework. Stratis is a worldwide operating company, formed by a distributed team of business managers, developers, consultants, marketing and sales experts to solve the challenges of enterprise blockchain development and implementation on a global scale. Stratis is headquartered in the U.K. and incorporated as Stratis Group Ltd. For more information, visit: www.stratisplatform.com. About Crypto.com Crypto.com was founded in 2016 to accelerate the world's transition to cryptocurrency. Key products include: the Crypto.com App, the best place to buy, sell, and pay with crypto, the MCO Visa Card, a metal card with no annual fees, and the Crypto.com Chain, which enables users to pay and be paid in any crypto, anywhere, for free. Crypto.com is headquartered in Hong Kong with a 150+ strong team. For more information, please visit: www.crypto.com. For press enquiries, please contact: The Hoffman AgencyCryptoPR@hoffman.com Photo - https://mma.prnewswire.com/media/964623/Crypto_STRAT.jpg Logo - https://mma.prnewswire.com/media/750079/Crypto_Logo.jpg
-
Ethereum (ETH) Now Available on bitFlyer Buy/Sell
LUXEMBOURG--(BUSINESS WIRE)--Cryptocurrency exchange bitFlyer has announced it is adding Ethereum (ETH) to its Buy/Sell trading platform. From today, bitFlyer Buy/Sell users across Europe and the US can send and receive ETH while ensuring they adhere to the same robust regulatory standards as bitFlyer guarantees for Bitcoin (BTC) transactions. Andy Bryant, Co-head and COO, bitFlyer Europe, said, “At bitFlyer, we want to offer not just the most popular coins, but the most respected ones too, which makes ETH a logical choice to expand our service offering. Not only has ETH proved itself as a useful altcoin, particularly in relation to smart contracts, it has an incredibly strong community that surrounds it. We’re committed to offering the best customer experience whilst prioritising security and regulatory standards, and we’re proud to say Buy/Sell now offers this capability with ETH.” Hailey Lennon, Head of Legal and Regulatory Affairs, bitFlyer USA, said "As crypto regulation is evolving, we work to ensure that everything listed on our exchange complies with the global regulatory standards. We're excited for today's announcement, adding Ether to our growing portfolio of coins with NYDFS approval, and we're looking forward to launching more coins in the coming months." The addition of ETH comes after both bitFlyer Europe and bitFlyer USA announced its Buy/Sell platform last month, a new trading platform for anyone wanting a simple way to buy and sell digital currency. Before the launch of bitFlyer Buy/Sell, bitFlyer offered customers its pro-trader Lightning platform, which acted as a BTC/EUR and BTC/USD marketplace, respectively, between traders. bitFlyer Buy/Sell users will be able to buy and sell BTC, and now ETH, on the platform. bitFlyer launched in the USA in November 2017, followed by Europe in January 2018, both as fully owned subsidiaries of bitFlyer, Inc., a household name in the cryptocurrency space and one of the longest-standing cryptocurrency exchanges. bitFlyer is the only cryptocurrency exchange to be licensed in Japan, the US and Europe combined, and has also recently been recognised as one of only 10 exchanges that does not fake trading volumes data. bitFlyer is passionate about the future of the cryptocurrency industry and aims to support that future by setting the global standard for exchanges. bitFlyer believes that industry standards and regulation are fundamental to the future of the industry and is often involved in conversations at the highest level, including having taken part in the recent G20 discussions. It was also involved in the amendment to the Payments Act in Japan which famously recognised Bitcoin as legal tender. ENDS About bitFlyer EUROPE S.A. bitFlyer EUROPE S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell digital currencies. bitFlyer EUROPE S.A. corporate site: bitflyer.com/en-eu/ About bitFlyer USA, Inc. bitFlyer USA, Inc. is a wholly-owned subsidiary of bitFlyer, Inc., a leading Bitcoin and blockchain company based in Japan. The US office is located in San Francisco and operates an exchange platform for US traders to buy and sell Bitcoin. Launching in the U.S. in 2017, bitFlyer USA currently operates in 46 states and territories, including New York with the New York Bitlicense. bitFlyer USA, Inc., corporate site: www.bitflyer.com/en-us Contacts Lauren Armour Lauren.armour@tytopr.com 07826 557 326
-
Global Artificial Intelligence (AI) Market in Healthcare Sector 2019-2023 | 28% CAGR Projection Over the Next Five Years | Technavio
LONDON--(BUSINESS WIRE)--#ApplicationSoftware--The global artificial intelligence (AI) market in healthcare sector 2019-2023 is expected to post a CAGR of more than 28% during the period 2019-2023, according to the latest market research report by Technavio. Request a free sample report The healthcare industry is undergoing a digital revolution, with the growing penetration of various IT-based processes. The advent of smartphones and the increasing penetration of the Internet across the world are fueling connectivity in healthcare that offers numerous benefits. Digitalized healthcare simplifies the delivery of healthcare services and helps in easy and secure management of patient data. The increasing connectivity is driving the demand for advanced technologies, such as AI and advanced analytics. Thus, the increasing digitalization in the healthcare industry will drive the growth of the market during the forecast period. Looking for more information on this market? Request a free sample report As per Technavio, the growing potential for AI-based tools in elderly care will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023. Global Artificial Intelligence (AI) Market in Healthcare Sector: Growing Potential for AI-Based Tools in Elderly Care Healthcare providers have started using AI widely for intelligent tracking of biometric information and early diagnosis of diseases. Moreover, they are now opting for AI to automate certain parts of care pathways to meet the growing requirements of elderly patients. The applications of AI include smart devices, assisted living, fall detection, home health monitoring, and virtual companions such as elderly care robotics. Thus, the growing potential for AI-based tools in elderly care will drive the demand for AI in the healthcare landscape. “Apart from the growing potential of AI-based tools in elderly care, other factors such as the growing popularity of precision medicine, and the emergence of AI-based solutions for improving mental health will have a significant impact on the growth of the artificial intelligence (AI) market in the healthcare sector during the forecast period,” says a senior analyst at Technavio. Global Artificial Intelligence (AI) Market in Healthcare Sector: Segmentation Analysis This market research report segments the global artificial intelligence (AI) market in the healthcare sector by application (medical imaging and diagnostics, drug discovery, operations management, virtual assistants, and others), and geographical regions (Europe, North America, APAC, South America, and MEA). The North American region led the AI market in healthcare industry in 2018, followed by Europe, APAC, South America, and MEA, respectively. The dominance of North America can be attributed to several factors such as early adoption and increasing investments by market players. The rising adoption of machine learning (ML) is also contributing to the high market share of this region. Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report Some of the key topics covered in the report include: Market Landscape Market ecosystem Market characteristics Market segmentation analysis Market Sizing Market definition Market size and forecast Five Forces Analysis Market Segmentation Geographical Segmentation Regional comparison Key leading countries Market Drivers Market Challenges Market Trends Vendor Landscape Vendors covered Vendor classification Market positioning of vendors Competitive scenario About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. If you are interested in more information, please contact our media team at media@technavio.com. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 www.technavio.com
-
World’s First Palm Oil Free Certification Trademark Now Approved in Benelux
ADELAIDE, Australia--(BUSINESS WIRE)--#climate--POFCAP -- On August 19 2017 (International Orangutan Day), POFCAP launched the world’s first Palm Oil Free Certification Trademark in Australia. Now, 2 years on, POFCAP celebrates its second birthday with 1,088 products Certified Palm Oil Free with hundreds more currently under assessment. The trademark is approved in 19 countries - Australia, Scotland, Spain, N. Ireland, Austria, England, Wales, Sweden, the USA, Italy, France, Finland, NZ, Singapore, Norway, India and just announced, Belgium, Luxembourg and The Netherlands. Jabrick - the cheeky little orang-utan featured on the certification trademark who was herself a victim of deforestation will soon be seen on packaging globally. (see Jabrick’s story on the POFCAP website) Since inception there have been many World Firsts for POFCAP. Of particular note are the world first assessments of - a Vegetable Oil Producer and Manufacturer (MSM Milling/Australia), a Vitamin Brand (Viridian Nutrition/England), a ‘Free From’ Snack Company (Enjoy Life Foods/ USA), an Infant Formula (LittleOak/NZ), a Café(El Piano/England), a Cooking School (Squaw Pies/Scotland), a Cosmetic Brand(Sugar Venom/Australia), a Skincare Brand (Amaranthine/Scotland) and a Raw Material Manufacturer (Afyren/France). The use of palm oil is exceptionally widespread with the majority of supermarket products containing either palm oil or one of its many thousands of derivatives. The topic evokes robust discussion around both health and environment. With over 80% of palm oil being produced unsustainably the concerns surrounding the impact on rainforests, wildlife and the climate crisis has seen many more people seeking products which are genuinely palm oil free, but, unless the product has been assessed by an independent and approved certification programme it is almost impossible to tell which palm oil free claims are correct as many are not. About the International Palm Oil Free Certification Trademark (POFCAP) POFCAP the only International Palm Oil Free Certification Trademark in the World launched in Australia in late 2017 and is now Global with approval to certify brands in 20 countries. POFCAP assesses products as to their palm oil free status. Two of the programme’s aims are to assist consumers who wish to avoid palm oil for allergy, dietary or ethical reasons when shopping for genuine, independently assessed palm oil free products and distribute 100% of profits to POFCAP’s Partner NGOs working to protect rainforests. For further information: www.palmoilfreecertification.org Contacts Palm Oil Free Certification Trademark Bev Luff E: pofcertification@iinet.net.au
-
CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting
SUZHOU, China, Aug. 23, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO, 2019 CSCO Annual Meeting) has accepted three abstracts on the clinical trials of CS1001 (Anti-PD-L1 antibody), CS1002 (Anti-CTLA-4 antibody), and CS1003 (Anti-PD-1 antibody), the Company's three backbone immunotherapy candidates. Meanwhile, three late-breaking abstracts on the CS1001-101 Phase Ib clinical trial have also been submitted for presentation. CS1001-101 Trial The CS1001-101 trial is a Phase Ia/Ib open-label, multiple-dose, dose-escalation, and dose-expansion study assessing the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of CS1001 in Chinese patients with advanced solid tumors or lymphomas. Currently, CS1001 is being investigated in multiple clinical trials in China and the U.S., and over 650 patients have been enrolled in these studies. The results that will be released in poster presentation at the 2019 CSCO Annual Meeting include: The safety data from the CS1001-101 Phase Ia/Ib clinical trial, and the efficacy data from the Phase Ib trial in cholangiocarcinoma (Abstract #4763). Three late-breaking abstracts have also been submitted for oral presentation at the meeting include: The safety and efficacy data from the CS1001-101 Phase Ib trial in patients with esophageal carcinoma. The safety and efficacy data from the CS1001-101 Phase Ib trial in patients with gastric cancer. The safety and efficacy data from the CS1001-101 Phase Ib trial in patients with MSI-H cancers. CS1002-101 Trial The CS1002-101 trial is an open-label, multiple-dose, dose-escalation, and dose-expansion study conducted in Australia assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor efficacy of CS1002 in patients with advanced solid tumors. At present, the study has completed the dose-escalation stage of CS1002 monotherapy. The dose-escalation of combination with CS1003 in solid tumors and the dose-expansion of the combination in selected tumor types have been planned. The data that will be released in oral presentation at the 2019 CSCO Annual Meeting includes: Preliminary safety, pharmacokinetics and pharmacodynamics results from a Phase Ia study of CS1002 in patients with advanced solid tumors (Abstract #4756). CS1003-102 Trial The CS1003-102 trial is a multi-center Phase I study evaluating the safety, tolerability, and preliminary anti-tumor activity of CS1003 in Chinese patients with advanced solid tumors and lymphomas. CS1003 is currently undergoing Phase I clinical studies in China and Australia, and received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) in October 2018. The results that will be released in oral presentation at the 2019 CSCO Annual Meeting include: Preliminary safety, pharmacokinetics and efficacy results from a phase I study of CS1003 in Chinese patients with advanced solid tumors or lymphoma (Abstract #4847). About CS1001 CS1001 is an investigational monoclonal antibody directed against PD-L1 being developed by CStone. Authorized by the U.S. based Ligand Corporation, CS1001 is developed by the OMT transgenic animal platform, which can generate fully human antibodies in one step. As a fully human, full-length anti-PD-L1 monoclonal antibody, CS1001 mirrors natural G-type immune globulin 4 (IgG4) human antibody, which can reduce the risk of immunogenicity and potential toxicities in patients, potentially representing a unique advantage over similar drugs. CS1001 has completed a Phase I dose-escalation study in China, in which CS1001 showed good tolerability and produced sustained clinical benefits during the Phase Ia stage of the study. CS1001 is being investigated in a number of ongoing clinical trials, including one Phase I bridging study in the U.S. In China, its clinical program includes one multi-arm Phase Ib study, two pivotal Phase II studies, and three Phase III studies for several tumor types. About CS1002 and the CTLA-4 pathway CS1002 is an investigational anti-CTLA-4 monoclonal antibody being developed by CStone. Cytotoxic T lymphocyte associated antigen 4 (CTLA-4), also known as CD152, is a transmembrane protein encoded by the CTLA-4 gene that can down-regulate the activity of T cells when binding with its ligand, B7, a pathway also used by tumor cells to avoid T lymphocyte attack. Consequently, blockade of the CTLA-4 pathway can stimulate T cell activation and proliferation to induce or enhance anti-tumor immune responses. CTLA-4 provides a new immuno-therapeutic approach to a number of diseases, including tumors. Presently, Bristol-Myers Squibb's Yervoy (ipilimumab) is the only anti-CTLA-4 antibody to gain a market approval worldwide, although Yervoy has not yet been approved in China. Pre-clinical tests have shown that CS1002 has a relatively strong affinity to CTLA-4 and is expected to match Yervoy in terms of efficacy. About CS1003 and the PD-1/PD-L1 pathway CS1003 is a humanized anti-PD-1 IgG4 monoclonal antibody developed by CStone using an internationally leading hybridoma platform. CS1003 has shown good tolerability and efficacy profile in preclinical in vivo studies. Unlike other anti-PD-1 mAbs, CS1003 recognizes both human and murine PD-1, providing a unique competitive advantage during efficacy testing in syngeneic mouse tumor models particularly for development of effective combination therapies. PD-1, or programmed death-1, is an inhibitory checkpoint receptor expressed on T cells. Under normal circumstances, it binds with its ligands, programmed death ligand-1 or ligand 2 (PD-L1/PD-L2), inhibiting T cell and cytokine activation, serving to dampen the immune response in order to prevent damage to healthy tissues. However, studies have shown that PD-L1 can be abundantly expressed on the surface of many solid tumors as well as hematological malignancies. Cancer cells can therefore make use of the PD-1/PD-L1 pathway to successfully avoid immune system recognition. Targeting of the PD-1/PD-L1 checkpoint by anti-tumor drugs can block the "tumor immune evasion mechanism" and restore anti-cancer immune ability in patients. About CStone CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, five late-stage candidates are at or near pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. For more information about CStone Pharmaceuticals, please visit: www.cstonepharma.com. Forward-looking Statement The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.Related Links :www.cstonepharma.com
-
CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study
SUZHOU, China, Aug. 23, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received ethics approval from the Human Research Ethics Committee in Australia for the Phase I clinical trial of CS3002, and Australia's Therapeutic Goods Administration (TGA) has acknowledged the electronic Clinical Trial Notification (eCTN) the Company submitted for the trial. This clinical trial is an open-label, multi-dose, dose-escalation, and dose-expansion Phase I clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of CS3002 in patients with advanced solid tumors. Being developed by CStone, CS3002 is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6). Inducing cell cycle arrest of tumor cells through the selective inhibition of CDK4/6, CS3002 has demonstrated high therapeutic potential for combination with endocrine therapy or immune checkpoint inhibitor therapy in various solid tumors. At present, three CDK4/6 inhibitors have been approved by the U.S. FDA. However, in China, palbociclib is the only approved CDK4/6 inhibitor, indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women. Preclinical studies have revealed that CS3002's in vivo and in vitro activities are comparable to that of palbociclib's. In mouse models, CS3002 combined with PD-1 monoclonal antibody therapy or endocrine therapy has shown improved tumor suppressing activities compared to monotherapies. In addition, CS3002 has also demonstrated potentially favorable safety and tolerability profiles. Dr. Frank Jiang, Chairman and CEO of CStone, commented: "Currently, there are several CDK4/6 inhibitors that are either approved or in clinical development in the world. However, options in this class of therapies available to Chinese patients remain very limited and no domestically developed CDK4/6 inhibitor has been approved. I am pleased that we are about to initiate the Phase I trial on CS3002 in Australia. We will accelerate our work in obtaining its clinical trial approval in China and actively explore CS3002's application in the treatment of various tumor types and different combination therapies. We hope CS3002 will become a new effective treatment option benefiting Chinese patients." Dr. Jon Wang, CStone's Chief Scientific Officer, noted: "The aberrant activation CDK4/6 was observed across various tumor types, suggesting CS3002's potential utility in the treatment of breast cancer and a variety of other solid tumors. Recent studies have shown that, in addition to inducing cell cycle arrests, CDK4/6 inhibitors also have the effects of strengthening anti-tumor immunity and modulating the tumor microenvironment. These discoveries provide the foundation for a new approach in cancer treatment, which is the combination of CDK4/6 inhibitors and immunotherapies. We are hopeful that the clinical trial on CS3002 in Australia will be carried out successfully." About CS3002 CS3002 is a new generation of well-tolerated and highly selective CDK4/6 inhibitor developed by CStone. CDK4/6 inhibitors are the cyclin-dependent kinases that play a crucial role in the regulation of cell cycle progression from the first Growth phase (G1 phase) to the Synthesis phase (S phase). Upon activation of the cell proliferation signal, cyclin D protein binds to CDK4/6. The cyclin D–CDK4/6 complex then phosphorylates downstream retinoblastoma (Rb) protein, resulting in the aberrant proliferative signaling in the CDK4/6 pathway that drives the cell cycle progression from the G1 phase to the S phase. Aberrant CDK activity is a common feature of most cancer types. CDK4/6 inhibitors could suppress the activities of CDK4/6 and the phosphorylation of Rb protein, thereby achieving the suppression of tumor cell growth by interrupting the cell cycle transition from the G1 phase to the S phase. The commonality of aberrant cyclin D–CDK4/6–INK4–Rb pathway signaling in a tumor cells suggests CDK4/6 inhibitors' potential application in strengthening anti-tumor immunity, and CDK4/6 inhibitors' promising potential for the treatment of various solid tumors and synergistic combination with immuno-oncology therapies. About CStone CStone Pharmaceuticals (HKEX:2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, five late-stage candidates are at or near pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. For more information about CStone Pharmaceuticals, please visit: www.cstonepharma.com. Forward-looking Statement The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.Related Links :www.cstonepharma.com
-
Bin Zayed Group's global oil chain and BBOSS reached a strategic cooperation
NEW YORK--(BUSINESS WIRE)--Recently, Top investment master in the world, Prince of Abu Dhabi, Chairman of the Board of Directors of the Bin Zayed Group, His Excellency Sheikh Khaled Bing Zayed Al Nahyan, Chairman of the Board of Directors of the Abu Dhabi Sovereign Fund, chaired the “Global refueling chain OPC Strategic Cooperation Seminar” in Bangkok, Thailand. The Bin Zayed Group, a partner from 50 countries around the world, held a one-day strategic discussion on the use of the BBOSS accounting tool to launch the global refueling chain. Finally reached a consensus that the OPC global refueling system uses the BBOSS accounting tool as a third-party tool for OPC points. Liu Shijiang, secretary general of the China Aviation Rescue Alliance, attended the seminar and reached a strategic cooperation intention on the cooperation between the Air Rescue Association and OPC. (BIN ZAYED GROUP, (BZG),) is a global oil, energy, bank, finance, real estate, top hotel, antique and cultural relics investment enterprise founded by Prince Sheikh Khaled Bin Zayed Al Nahyan. Its “Abu Dhabi sovereign fund”, with a size of $1.3 trillion (10 trillion yuan), once ranked first in the world and now ranks second in the world. The global refueling chain project launched by the Bin Zayed Group is the first subdivided market project based on block chain technology to solve the problem of gas stations. This project not only solves the problem of expensive refueling, The problem of the number of passengers at gas stations is due to the use of the BBOSS points tool to give all participants more benefits. The global network of global refueling chain projects will make full use of the BBOSS accounting tool, meaning that the physical application of BBOSS tools is rapidly expanding to more areas around the world. The cooperation with the China Aviation Rescue Alliance also applies the oil chain to people’s livelihood, refueling BBOSS Token to let more consumers feel the convenience and benefits of BBOSS accounting tools to their lives. Contacts Jan Liu Jan@globalnews.com
-
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Textron Inc. and Encourages Investors with Losses
LOS ANGELES--(BUSINESS WIRE)--$TXT #TXT--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Textron Inc. (“Textron” or “the Company”) (NYSE: TXT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between January 31, 2018 and October 17, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 21, 2019. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Textron suffered from slowing end-market sales of Arctic Cat products, leaving the sales channel filled with excess inventory. The Company provided significant discounts in an effort to clear the aging inventory, which impacted its earnings. Based on these facts, the Company’s public statements were false and materially misleading. When the market learned the truth about Textron, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Contacts The Schall Law Firm Brian Schall, Esq. www.schallfirm.com Office: 310-301-3335 Cell: 424-303-1964 info@schallfirm.com
